Library
PubMed
research article
Professional

CONCURRENTCOLITIS AND CYTOMEGALOVIRUS INFECTION AS A CAUSE OF PERSISTENT DIARRHEA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-HODGKIN LYMPHOMA FOLLOWING BENDAMUSTINE-BASED CONDITIONING.

Source: PubMed, NCBI / U.S. National Library of Medicine

Acta clinica CroaticaSedinić Lacko Martina, Mitrović Zdravko, Crnek Sandra Šestan, et al.Published 6/1/2025Last synced 6/10/2026Status: syncedPMID: 41635671DOI: 10.20471/acc.2025.64.02.23

Diarrhea usually appears early following autologous hematopoietic stem cell transplantation (ASCT) due to toxic mucosal damage and neutropenia. Infectious agents also cause diarrhea in the post-transplantation period, withbeing most common. In contrast, cytomegalovirus (CMV) enterocolitis is extremely rare after ASCT. We report a case of a 55-year-old male who underwent ASCT for non-Hodgkin lymphoma that was complicated by severe persistent diarrhea resulting in significant hypovolemia and electrolyte imbalance. Prior to transplantation, the patient received rituximab in combination with chemotherapy (R-CHOP/R-DHAP) followed by a bendamustine-based conditioning regimen (BeEAM). After treatment with oral metronidazole, vancomycin and fidaxomicin, diarrhea persisted despite undetectabletoxin, with elevation of hepatic enzymes. Eventually, CMV infection was diagnosed by real-time polymerase chain reaction and treated with ganciclovir and valganciclovir. Due to hypogammaglobulinemia following previous rituximab treatment, CMV immunoglobulins were also administered. The patient's condition gradually improved with CMV DNA being undetectable in serum. This case shows that diarrhea may be caused by concurrent infection withand CMV after ASCT. Bendamustine-induced colitis and prior rituximab treatment may have been additional risk factors in this patient. Therefore, more comprehensive workup of diarrhea is needed in ASCT recipients treated with these agents.

Educational only
This information is for general education and is not medical advice. Always talk to a licensed U.S. clinician about your situation, medications, or treatment decisions.